PDF(Pubmed)
Abstract：
UNASSIGNED: Besides transcatheter edge-to-edge repair (TEER), there are new interventional treatment options for mitral and tricuspid regurgitation in evaluation, such as a complete replacement of the valve through a prosthesis.
UNASSIGNED: A 78-year-old previous coronary artery bypass graft-operated patient with symptomatic severe mitral regurgitation and tricuspid regurgitation was sequentially treated by a transfemoral transcatheter mitral and tricuspid valve prosthesis (Cardiovalve; Cardiovalve Ltd, Israel) due to unfavourable mitral valve anatomy. The transcatheter mitral valve implantation (TMVI) was performed first and after progression of the tricuspid regurgitation, a second transcatheter valve prosthesis was implanted in tricuspid position (TTVI) 1.5 years later. Imaging showed a twin look-alike picture of a mitral and tricuspid prosthesis and showing the possibility of a complete transcatheter based replacement of the mitral and tricuspid valve.
UNASSIGNED: This case shows the possibility of a Cardiovalve prosthesis being used for TMVI and TTVI in a single patient. Especially in TEER ineligible patients, it might be a good treatment option after device approval.
UNASSIGNED: A 78-year-old previous coronary artery bypass graft-operated patient with symptomatic severe mitral regurgitation and tricuspid regurgitation was sequentially treated by a transfemoral transcatheter mitral and tricuspid valve prosthesis (Cardiovalve; Cardiovalve Ltd, Israel) due to unfavourable mitral valve anatomy. The transcatheter mitral valve implantation (TMVI) was performed first and after progression of the tricuspid regurgitation, a second transcatheter valve prosthesis was implanted in tricuspid position (TTVI) 1.5 years later. Imaging showed a twin look-alike picture of a mitral and tricuspid prosthesis and showing the possibility of a complete transcatheter based replacement of the mitral and tricuspid valve.
UNASSIGNED: This case shows the possibility of a Cardiovalve prosthesis being used for TMVI and TTVI in a single patient. Especially in TEER ineligible patients, it might be a good treatment option after device approval.
摘要：
■除了经导管边缘到边缘修复(TEER),在评估中，二尖瓣和三尖瓣返流有新的介入治疗方案，例如通过假体完全替换瓣膜。
■一名78岁的既往冠状动脉搭桥术患者，有症状的严重二尖瓣返流和三尖瓣返流，通过经股动脉导管二尖瓣和三尖瓣假体依次治疗（Cardiovalve；CardiovalveLtd，以色列）由于二尖瓣解剖结构不利。首先进行经导管二尖瓣植入术（TMVI），并在三尖瓣返流进展后进行。1.5年后在三尖瓣位置(TTVI)植入第二个经导管瓣膜假体.成像显示二尖瓣和三尖瓣假体的双胎相似图像，并显示了经导管完全置换二尖瓣和三尖瓣的可能性。
■该病例显示了在单个患者中用于TMVI和TTVI的心脏瓣膜假体的可能性。特别是在TEER不合格的患者中，在设备批准后，这可能是一个很好的治疗选择。
■一名78岁的既往冠状动脉搭桥术患者，有症状的严重二尖瓣返流和三尖瓣返流，通过经股动脉导管二尖瓣和三尖瓣假体依次治疗（Cardiovalve；CardiovalveLtd，以色列）由于二尖瓣解剖结构不利。首先进行经导管二尖瓣植入术（TMVI），并在三尖瓣返流进展后进行。1.5年后在三尖瓣位置(TTVI)植入第二个经导管瓣膜假体.成像显示二尖瓣和三尖瓣假体的双胎相似图像，并显示了经导管完全置换二尖瓣和三尖瓣的可能性。
■该病例显示了在单个患者中用于TMVI和TTVI的心脏瓣膜假体的可能性。特别是在TEER不合格的患者中，在设备批准后，这可能是一个很好的治疗选择。
